BioCentury | Jan 16, 2015
Company News

China's 3SBio in-licenses second PharmAbcine mAb

...Daejon, South Korea) granted 3SBio Inc. (Shenyang, China) an exclusive license to develop DIG-KT ( TRPH 011...
BioCentury | Jan 16, 2015
Company News

China's 3SBio in-licenses second PharmAbcine mAb

...Daejon, South Korea) granted 3SBio Inc. (Shenyang, China) an exclusive license to develop DIG-KT ( TRPH 011...
BioCentury | Nov 3, 2014
Company News

Triphase, Celgene deal

...an option to license exclusive, worldwide rights, excluding China and Korea, to develop and commercialize TRPH 011...
...eligible for regulatory and sales milestones. Triphase gained worldwide rights, excluding China and Korea, to TRPH 011...
BioCentury | Nov 3, 2014
Company News

PharmAbcine, Triphase deal

...PharmAbcine granted Triphase exclusive, worldwide rights, excluding China and Korea, to develop and commercialize TRPH 011...
BioCentury | Oct 29, 2014
Company News

Triphase signs cancer pacts with Celgene, PharmAbcine

...Corp. (San Diego, Calif.) in-licensed global rights excluding China and Korea to preclinical oncology candidate TRPH 011...
...from PharmAbcine Inc. (Daejon, South Korea). Concurrently, Celgene Corp. (NASDAQ:CELG) purchased an option to acquire TRPH 011...
...upfront payment from Triphase and is eligible for milestones and royalties. Triphase and PharmAbcine said TRPH 011...
Items per page:
1 - 5 of 5